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health care professionals and health economists from the begin-
ning of MD development; and deﬁning MD to be evaluated in
priority, on which economic evaluation methods should be tested
before being applied to others.
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OBJCETIVE: To evaluate the basic knowledge level of DM
(General manager of the Hospital-GMH- and Chief of clinical
service-SCS-) about the application of PE/HE tool as inﬂuence
characteristics in decision make as well as main advantages and
obstacles. METHODS: A transversal survey was performing. In
a not related forum, DM was invited to complete a self-report
questionnaire about utilization of concepts of PE/HE in local
health care decision make. The main inclusion criteria were the
DM taken part in the process of evaluation inclusions of drugs
on the basic formulary. Descriptive and multivariate analysis test
were applied. RESULTS: A total of 139 questionnaires were
included for the analysis. Male 76.98%, the mean of (SD): age
48.28 (+6.35), time of labour experience 19.5 (+7.02). The
30.22% was SCS and 14.39% were GMH. The more important
characteristics for inclusions of drugs on the basic formulary are
efﬁcacy (82.73%) and safety and tolerability (76.94%). The
PE/HE was ﬁfth (64.03%). 44.60% had training in PE/HE
topics. Cost-beneﬁt was the concept mentioned more frequently
(75.54%). The 68.35% used PE/HE for inclusions of drugs on
the basic formulary. The probability of using PE/HE is 3.97 times
stolen high if DM has taken PE/HE course. The perception of
the group of the advantages de PE/HE help them to optimize the
resource (54.68%) and to give validation and realiable informa-
tion (7.91%). About the obstacle of use of PE/HE, DM men-
tioned the difﬁcult of access of the PE/HE (36.20%) and lack of
training (20.69%). A low percentage of participate wrote correct
the concepts of PE/HE. CONCLUSIONS: It is important to
strengthen the knowledge and utilization of the PE/HE tools in
Mexican DM.
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OBJECTIVES: Utilities are increasingly used to measure quality
of life (QoL) for health states, and a variety of instruments can
be used for this purpose. When QOL measures for different
groups are obtained using different instruments, comparing
summary statistics formally is difﬁcult and there is nothing
described in the methodology or applied literature. In this pre-
sentation we propose a relatively simple approach for compar-
ing QoL mean scores from EuroQoL and AqoL questionnaires
indirectly when this situation is encountered, which leads to a
result equivalent to that of a t-test. METHODS: Using an
example from a utility study for illustration, we describe a
method based on multiple imputation (MI), an approach com-
monly used to deal with missing data. From an estimate of the
correlation between the total mean scores, we describe how
simple linear regression can be used to obtain imputed values of
EuroQoL scores from AQoL scores. The multiple imputation
approach then offers simple techniques to obtain pooled esti-
mates of mean difference and variance on the EuroQoL scale.
RESULTS: We show how the resulting data can be used in a
simple way to generate a valid t-test statistic on the same QoL
scale. We then brieﬂy discuss the strengths and weaknesses of
this approach from the point of view of QoL measures as well
as methodology. CONCLUSIONS: The approach we present can
be used to compare data from different QoL instruments. We
summarise the circumstances under which such comparisons
would be valid, and also highlight situations when this approach
should not be used.
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OBJECTIVES: To describe the development and validation of a
Dutch version of the London Handicap Scale (DLHS). This ques-
tionnaire was based on the London Handicap Scale, a valid and
reliable utility instrument for measuring social participation in
adults. METHODS: The DLHS was tested in 803 adults with a
questionnaire consisting of the DLHS itself, the Impact on Par-
ticipation and Autonomy’ questionnaire (IPA), the Dutch version
of the EuroQol EQ-5D and questions concerning e.g. chronic
diseases, use of medical devices. The study population consisted
of patients with rheumatoid arthritis, cara/asthma, epilepsy,
larynchetomy and multiple sclerosis. RESULTS: Content valida-
tion, evaluated by relating the scores on the dimensions of the
DLHS and the number of chronic diseases was satisfactory. Con-
ceptual validation was shown by large (or some moderate,
almost large) correlations of predeﬁned pairs of the DLHS
dimensions with domains of the IPA. Correlations between the
DLHS sumscore and the IPA subscales were considerably larger
than corresponding correlations between the EQ-5D and the IPA
subscales, indicating a good concurrent validity of the DLHS.
The ability of the DLHS to discriminate between various sub-
groups of chronically ill persons ﬁve criteria was shown by cor-
relating the DLHS sumscore with ﬁve predeﬁned criteria.
CONCLUSIONS: Based on this evaluation the questionnaire
seems feasible and valid for assessing differences between differ-
ent subgroups of chronically ill or disabled persons in The
Netherlands.
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OBJECTIVES: Desferal (DFO), the most common CT for IO,
requires infusions of 8–12 hours, 5–7 days per week. Oral for-
mulations are in development. Consequences of the high burden
of current chelation therapy with Desferal are poor treatment
adherence and satisfaction potentially leading to sub-optimal
clinical outcome. However, CT-speciﬁc satisfaction question-
naires have not been developed. METHODS: Five steps were
taken to develop the satisfaction questionnaire: literature review,
patient interviews, clinician interviews, item generation and
content validity testing. Three IO expert interviews and four
patient interview transcripts were reviewed to assess satisfaction
with DFO and reactions to a hypothetical oral CT. Items were
developed based on these steps and tested in nine patients
